Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
- Immuron (ASX:IMC) enters research agreement with Monash University
- Walter Reid Army Institute of Research 2019 Year in Review
- Immuron reveals anti-COVID potential, raises $28 million
- Diarrhea: A major health issue for Americans travelling abroad
- Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
- Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.